Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and non-glycaemic effects, including improved insulin secretion and action, body-weight loss, blood-pressure lowering and improved lipid profile, as well as via direct effects on the heart and vasculature. These actions are likely combined with anti-inflammatory and antioxidant properties that translate into robust and consistent reductions in atherothrombotic events, particularly in people with type 2 diabetes and established atherosclerotic CVD. GLP-1RAs may also have an impact on obesity and chronic kidney disease, conditions for which cardiovascular risk-reducing options are limited. The available evidence has prompted professional and medical societies to recommend GLP-1RAs for mitigation of the cardiovascular risk in people with type 2 diabetes. This review summarises the clinical evidence for cardiovascular protection with use of GLP-1RAs and the main mechanisms underlying this effect. Moreover, it looks into how the availability of upcoming dual and triple incretin receptor agonists might expand the possibility for cardiovascular protection in people with type 2 diabetes. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Cardiovascular outcomes and all-cause mortality for GLP-1RAs. Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the meta-analysis by Sattar et al [26], which included all available data from GLP-1RA CVOTs except for FREEDOM CVO. 3P-MACE consisted of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. Data for myocardial infarction and stroke are for both fatal and non-fatal events. Data are plotted on a logarithmic scale (log10). This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/5a910b6263014ddd91c3dcdfaf8bedfe/incretins-and-cardiovascular-disease-to-the-heart-of-type-2-diabetes-figure-2.jpg)
![Fig. 3 Generalisability of results from GLP-1RA CVOTs to the real-world type 2 diabetes population. The infographic shows the proportion of individuals in the general adult type 2 diabetes population from Spain [30], the UK [31], and the USA [32] that would have been eligible for enrolment in the LEADER [17], SUSTAIN-6 [18] and REWIND [25] trials (sorted by publication date) according to the trials’ key selection criteria. General population with type 2 diabetes, grey; eligible individuals for study enrolment, blue. T2D, type 2 diabetes. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/939f0d750a4d4263b69a5fc568edbb25/incretins-and-cardiovascular-disease-to-the-heart-of-type-2-diabetes-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 'cardiovascular outcome trials' with GLP1RAs have generally shown protective effects against major adverse cardiovascular events, but different members of the class have exerted different effects on CV deaths, non-fatal myocardial infarction and non-fatal stroke as well as improving heart failure prognosis in some studies [72-74].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 11×
“Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the me…”
BackgroundMethodInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 10×
“Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the me…”
BackgroundMethodInfluentialOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 6×
“Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the me…”
BackgroundMethodInfluentialEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 5×
“Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the me…”
BackgroundMethodResultInfluentialEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 3×
“In contrast, four CVOTs reported neutral effects on 3P-MACE with long-term treatment with lixisenatide (the Evaluation of Lixisenatide in Acute Coronary Syndrome [ELIXA] trial) [21], oral semaglutide (the Peptide Innovation for Early Diabetes Treatment [PIONEER] 6 trial) [22], and exenatide prescribed as a once-weekly…”
BackgroundMethodJankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021) · Circulation · doi:10.1161/circulationaha.120.050686 · Cited by 1,904
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 2×
“94]) with no effect on cardiovascular mortality [3].”
BackgroundAssociation of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · cited 2×
“These results have revolutionised the therapeutic management of diabetes, moving from mere glycaemic targets towards a more holistic approach to the disease [83].”
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · cited 10×
“Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the me…”
BackgroundMethodInfluentialMargulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · cited 2×
“Accumulating evidence from clinical trials [67, 68] and real-world data [69] suggests that GLP-1RAs may offer additional renal benefits, which would translate into cardiovascular protection given the strong association between chronic kidney disease (CKD), ASCVD and HF [70].”
BackgroundJorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Zoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 356
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306 · cited 1×
“Moreover, post hoc analyses have provided initial support to an effect in terms of renal protection [93] and reductions in liver steatosis [94], two conditions contributing to cardiovascular risk in diabetes.”
BackgroundKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Exenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284 · cited 1×
“Anti-inflammatory and antioxidant properties of GLP1RAs, possibly mediated by GLP-1Rs expressed by gut intraepithelial lymphocytes and hepatic γδ T cells, have been reported in both animals [54] and humans [55].”
BackgroundYusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · cited 1×
“Proposed mechanisms include increased natriuresis, vasorelaxation and secretion of cardiac natriuretic peptides [48], although these effects appear to be attenuated with chronic use of GLP-1RAs and have not been confirmed in all studies [49].”
BackgroundKaragiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244 · cited 1×
“These include the sustained reduction of multiple proatherogenic risk factors, encompassing hyperglycaemia, obesity, arterial hypertension, systemic and tissue inflammation, liver steatosis, dyslipidaemia, platelet aggregation and albuminuria [39].”
BackgroundThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Woo, J. S., Kim, W., Ha, S. J., Kim, J. B., Kim, S.-J., Kim, W.-S., Seon, H. J., & Kim, K. S. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301586 · Cited by 223
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199
Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
Poornima, I., Brown, S. B., Bhashyam, S., Parikh, P., Bolukoglu, H., & Shannon, R. P. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182 · cited 1×
“Several mechanisms of protection against hospitalisation for HF have been demonstrated in different animal models, including increased myocardial glucose uptake, and reduced myocyte apoptosis, cardiac inflammation, adverse left ventricular remodelling, and atrial enlargement [71].”
BackgroundBuse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2251 · Cited by 175
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175 · cited 1×
“In people with non-alcoholic steatohepatitis (NASH), both liraglutide and semaglutide decreased liver inflammation and prevented fibrosis [57].”
BackgroundLovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2016.01.008 · Cited by 165
Glycemia reduction in type 2 diabetes–microvascular and cardiovascular outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200436 · Cited by 159
Giugliano, D., Longo, M., Signoriello, S., Maiorino, M. I., Solerte, B., Chiodini, P., & Esposito, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01474-z · Cited by 153
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
Wong, C. K., Yusta, B., Koehler, J. A., Baggio, L. L., McLean, B. A., Matthews, D., Seeley, R. J., & Drucker, D. J. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.003 · Cited by 138
Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Reheman, A., Siraj, M. A., Xu, X. R., Wang, Y., Lei, X., Afroze, T., Shikatani, E., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 137
Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057934 · Cited by 132
Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00340-0 · Cited by 131
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stančáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 129
Kosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14890 · Cited by 127
Chen, W. R., Hu, S. Y., Chen, Y. D., Zhang, Y., Qian, G., Wang, J., Yang, J. J., Wang, Z. F., Tian, F., & Ning, Q. X. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.014 · Cited by 123
Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 107
Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01584-3 · Cited by 102 · cited 7×
“The inclusion of the FREEDOM CVO trial in the meta-analysis [24], which employed a subcutaneous delivery system to ensure long-lasting elevation of the circulating GLP-1 analogue, did not influence the benefits of GLP-1RAs on 3P-MACE (n=64,236; HR 0.87 [95% CI 0.81, 0.94]) [27].”
BackgroundMethodInfluentialDave, C. V., Kim, S. C., Goldfine, A. B., Glynn, R. J., Tong, A., & Patorno, E. (2020) · Circulation · doi:10.1161/circulationaha.120.047965 · Cited by 101
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96 · cited 1×
“In mice, inactivation of the GIP receptor was associated with improved outcomes after experimental myocardial infarction [10], whereas GIP infusion was found to exert significant anti-atherogenic effects in mouse models of diabetes [11].”
BackgroundClegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0942-x · Cited by 94
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92 · cited 2×
“Glucagon has always been considered a main player in diabetes, as a counterregulatory hormone, although some interest was transiently generated because of its inotropic and chronotropic action [16].”
BackgroundNreu, B., Dicembrini, I., Tinti, F., Sesti, G., Mannucci, E., & Monami, M. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.013 · Cited by 89 · cited 1×
“GLP-1RAs neither reduce the risks for atrial fibrillation (and, thus, cerebral embolism) [75] or haemorrhagic stroke [76], nor do they acutely affect cerebral blood flow velocity [77].”
BackgroundLongato, E., Camillo, B. D., Sparacino, G., Gubian, L., Avogaro, A., & Fadini, G. P. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001451 · Cited by 88 · cited 1×
“At odds with such findings, others have documented that SGLT2i exert stronger protection against MACE and HF vs GLP-1RAs [37], as previously observed in some RCTs.”
ResultAn investigation of causal relationships between prediabetes and vascular complications
Mutie, P. M., Pomares‐Millan, H., Atabaki‐Pasdar, N., Jordan, N., Adams, R., Daly, N. L., Tajes, J. F., Giordano, G. N., & Franks, P. W. (2020) · Nature Communications · doi:10.1038/s41467-020-18386-9 · Cited by 86
McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82 · cited 1×
“Expression of GLP-1Rs has been detected at low levels in cardiomyocytes in atria and ventricles, endocardial and vascular endothelial cells, and vascular smooth muscle cells [46].”
BackgroundPasternak, B., Wintzell, V., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 74
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 71 · cited 1×
“Previous work has highlighted potential synergistic effects among members of the incretin family, leading to the development of multi-incretin agonists [90].”
BackgroundHemodynamic Effects of Glucagon: A Literature Review
Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00050 · Cited by 68 · cited 1×
“However, most of these studies were of small size and lacking rigorous control and, as such, any cardioprotective effect of glucagon remains uncertain [15].”
BackgroundRipa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Díaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 65 · cited 1×
“In mice, GLP-1RAs reduced aortic inflammation and prevented progression of atherosclerosis [58], whereas inconclusive findings have been reported in humans on the effects of GLP-1RA treatment on arterial inflammation [59] and carotid plaque composition and volume [60].”
BackgroundFerreira, J. P., Saraiva, F., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D., Packer, M., Zannad, F., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14997 · Cited by 65 · cited 1×
“A recent metaanalysis corroborates this hypothesis, reporting that GLP-1RAs prevent hospitalisation for new-onset HF but do not reduce HF readmissions in patients with previous HF history [28].”
ResultCahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Leiter, L. A., Bhatt, D. L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14179 · Cited by 58
Merino, J., Leong, A., Posner, D. C., Porneala, B., Masana, L., Dupuis, J., & Florez, J. C. (2017) · Diabetes Care · doi:10.2337/dc16-2625 · Cited by 53
Wei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 50
Boye, K. S., Riddle, M. C., Gerstein, H. C., Mody, R., García‐Pérez, L., Karanikas, C. A., Lage, M. J., Riesmeyer, J. S., & Lakshmanan, M. C. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13649 · Cited by 46
Trevisan, M., Fu, E. L., Szummer, K. E., Norhammar, A., Lundman, P., Wanner, C., Sjölander, A., Jernberg, T., & Carrero, J. J. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa004 · Cited by 44 · cited 1×
“A prospective observational study based on a Swedish registry (2010–2017) examined data from 17,868 people with type 2 diabetes who had survived their first myocardial infarction, 365 of whom were using GLP-1RAs (87% taking liraglutide, and 13% taking either exenatide, lixisenatide or dulaglutide) [34].”
MethodBaviera, M., Genovese, S., Lepore, V., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14361 · Cited by 42
Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation
Cahill, K. N., Amin, T., Boutaud, O., Printz, R., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., et al. (2022) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.04.004 · Cited by 41 · cited 1×
“In fact, liraglutide attenuated thromboxaneinduced platelet aggregation by 54% compared with sitagliptin or energy restriction in adults with impaired fasting glucose or impaired glucose tolerance [65], and a similar effect was observed in people with type 2 diabetes [66].”
BackgroundLee, M. M. Y., Kristensen, S. L., Gerstein, H. C., McMurray, J. J. V., & Sattar, N. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102382 · Cited by 37
Arnott, C. G., Neuen, B. L., Heerspink, H. J. L., Figtree, G. A., Kosiborod, M., Lam, C. S. P., Cannon, C. P., Rosenthal, N. R., Shaw, W. C., Mahaffey, K. W., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.06.011 · Cited by 35
Jujić, A., Atabaki-Pasdar, N., Nilsson, P. M., Almgren, P., Hakaste, L., Tuomi, T., Berglund, L. M., Franks, P. W., Holst, J. J., Prasad, R. B., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05093-9 · Cited by 33
Jujić, A., Nilsson, P. M., Atabaki-Pasdar, N., Dieden, A., Tuomi, T., Franks, P. W., Holst, J. J., Torekov, S. S., Ravassa, S., Díez, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1318 · Cited by 33
Koska, J., Migrino, R. Q., Chan, K. C., Cooper-Cox, K., & Reaven, P. D. (2021) · Diabetes Care · doi:10.2337/dc20-2014 · Cited by 31
Toulis, K. A., Hanif, W., Saravanan, P., Willis, B. H., Marshall, T. P., Kumarendran, B., Gokhale, K. M., Ghosh, S. K., Cheng, K. K., Narendran, P., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.02.003 · Cited by 28 · cited 1×
“Data from The Health Improvement Network (THIN) database, with contributions from over 640 UK general practices, have been used to compare matched type 2 diabetes patients who have been exposed (n=8345) or unexposed (n=16,541) to GLP-1RAs [33].”
MethodŽerovnik, Š., Kos, M., & Locatelli, I. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051549 · Cited by 27 · cited 1×
“In contrast, no significant effect was observed with regard to CVD-related death or HF [36].”
BackgroundYuan, S., Mason, A. M., Burgess, S., & Larsson, S. C. (2022) · Diabetes · doi:10.2337/db21-0905 · Cited by 25
Lopez, P. D., Bhatia, K., Bohra, C., Mahmood, K., Baruch, L., & Eng, C. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.012 · Cited by 25
Webb, J., Mount, J., von Arx, L., Rachman, J., Spanopoulos, D., Wood, R. P., Tritton, T., Massey, O., & IDRIS, I. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14580 · Cited by 24
Loganathan, J., Cohen, A. C., Kaloupis, G. M., Harris, C., Chronopoulos, A., James, V., Hamilton, J. R., Green, S., Wallis, A., Morgan, S. J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108188 · Cited by 19 · cited 1×
“In fact, liraglutide attenuated thromboxaneinduced platelet aggregation by 54% compared with sitagliptin or energy restriction in adults with impaired fasting glucose or impaired glucose tolerance [65], and a similar effect was observed in people with type 2 diabetes [66].”
BackgroundThuesen, L., Christiansen, J. S., Sørensen, K. E., Ørskov, H., & HENNINGSEN, P. (1988) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518809085396 · Cited by 18 · cited 1×
“At a physiological concentration, glucagon is not believed to exert significant effects on the heart, while at supraphysiological concentrations it increases heart rate and cardiac contractility [14].”
BackgroundPasternak, B., Wintzell, V., Eliasson, B., Svensson, J., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · doi:10.2337/dc20-1234/suppl.12016407.v1 · Cited by 17
Romera, I., Artime, E., Ihle, K., Díaz‐Cerezo, S., Santos, M. R., Prado, A. D., Cuenca, A. M. C., & Conget, I. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02196-0 · Cited by 7
Ölmestig, J. N. E., Marlet, I. R., Vilsbøll, T., Rungby, J., Rostrup, E., Lambertsen, K. L., & Kruuse, C. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899389 · Cited by 4
Comparative cardiovascular effects of GLP ‐1 agonists using real‐world data
Wallia, A., O’Brien, M. J., Hakimian, S., Kang, R. H., Cooper, A., Lancki, N., Stephen, J. J., Aikman, C., Liss, D. T., Parker, E. D., et al. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.339 · Cited by 2
Cited by
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Neves, J. S., Leite, A. R., Mentz, R. J., Holman, R. R., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3478 · Cited by 44
“26 The protective effect on HFpEF events may be explained by a decrease in epicardial mass and inflammation, an improvement of cardiovascular risk factors and/or a reduction of inflammatory markers.”
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 40
Solini, A., & Tricò, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15729 · Cited by 37
“100,101 As first-line therapies, SGLT2 inhibitors and both injectable and oral GLP-1RAs are recommended to improve cardiovascular risk factors and outcomes in subjects at high risk.”
Self-citationRecent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“…GLP-1RAs have generally shown protective effects against major adverse cardiovascular events, but different members of the class have exerted different effects on CV deaths, non-fatal myocardial infarction and non-fatal stroke as well as improving heart failure prognosis in some studies [72 – 74].”
Background
Metadata
- Authors
- Solini, A., Tricò, D., & Del Prato, S.
- Affiliations
- University of Pisa (IT)
- Venue
- Diabetologia
- Published
- 2023-08-05
- Volume
- 66
- Issue
- 10
- Pages
- 1820-1831
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC10473999
- OpenAlex
- W4385609776
- Cited by
- 32
- References
- 97
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 9 · 2023: 1
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Università di Pisa
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- GLP-1 receptor agonists, incretins, cardioprotection, type 2 diabetes, atherosclerotic cardiovascular disease, cardioprotection mechanisms, insulin secretion, blood pressure, lipid profile, obesity, chronic kidney disease, antioxidant and anti-inflammatory effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.